Principles and Practice Strategies for Immunotherapy in Genitourinary Malignancies

Published: Jan. 7, 2021, 5 a.m.

Guest: Yohann Loriot, MD, PhD
Guest: Robert J. Motzer, MD

Advances in immune checkpoint inhibitor therapy are transforming the way clinicians treat and manage metastatic UC and RCC. Given the approval of immune checkpoint inhibitors for the treatment of metastatic UC and RCC in recent years, and more emerging evidence, it can be challenging to understand how to best incorporate these therapies into current treatment strategies.

This activity will review the latest clinical advances, emerging data, and guideline recommendations for immunotherapy for the treatment of advanced renal cell carcinoma and urothelial carcinoma.